Use of 5alpha-reductase Inhibitors to Prevent Benign Prostatic Hyperplasia Disease

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2006 Aug 26

PMID 16930501

Authors

Leonard S Marks

Affiliations

Soon will be listed here.

Abstract

A histologic change in the prostate, benign prostatic hyperplasia (BPH), is a normal part of aging. However, BPH disease, defined here as a life-altering urinary condition caused by BPH requiring prompt medical intervention, is a serious medical disorder associated with major complications, surgical intervention, and severe lifestyle interference. BPH disease is preventable. The rationale for BPH disease prevention rests on four pillars of evidence: (1) BPH disease generally is a progressive disorder; (2) complications and severe lifestyle interference from BPH disease are common and serious; (3) men at greatest risk of BPH disease can be identified using prostate-specific antigen (PSA) level higher than 1.5 ng/mL as a surrogate marker for an enlarged prostate; and (4) 5alpha-reductase inhibitors (5ARIs) reduce the primary androgen responsible for prostate growth (dihydrotestosterone), shrink the prostate, and arrest the disease process regardless of symptom status. Thus, we now can identify men with an enlarged prostate at risk for BPH disease who may be candidates for preventive therapy with 5ARIs, regardless of urinary symptoms or bother.

References

Pasternak R, Smith Jr S, Bairey-Merz C, Grundy S, Cleeman J, Lenfant C . ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40(3):567-72. DOI: 10.1016/s0735-1097(02)02030-2. View

Andriole G, Humphrey P, Ray P, Gleave M, Trachtenberg J, Thomas L . Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004; 172(3):915-9. DOI: 10.1097/01.ju.0000136430.37245.b9. View

Andriole G, Kirby R . Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003; 44(1):82-8. DOI: 10.1016/s0302-2838(03)00198-2. View

LYTTON B, Emery J, HARVARD B . The incidence of benign prostatic obstruction. J Urol. 1968; 99(5):639-45. DOI: 10.1016/S0022-5347(17)62763-0. View

Wasson J, Bubolz T, Lu Yao G, Barry M . Prostate biopsies in men with limited life expectancy. Eff Clin Pract. 2002; 5(3):137-42. View

Jemal A, Tiwari R, Murray T, Ghafoor A, Samuels A, Ward E . Cancer statistics, 2004. CA Cancer J Clin. 2004; 54(1):8-29. DOI: 10.3322/canjclin.54.1.8. View

Wright E, Fang J, Metter E, Partin A, Landis P, Chan D . Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol. 2002; 167(6):2484-7; discussion 2487-8. DOI: 10.1016/s0022-5347(05)65010-0. View

Andriole G, Bruchovsky N, Chung L, Matsumoto A, Rittmaster R, Roehrborn C . Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004; 172(4 Pt 1):1399-403. DOI: 10.1097/01.ju.0000139539.94828.29. View

Garraway W, Russell E, Lee R, Collins G, McKelvie G, Hehir M . Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract. 1993; 43(373):318-21. PMC: 1372554. View

10.

Miller M, Puchner P . Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology. 1998; 51(2):237-40. DOI: 10.1016/s0090-4295(97)00614-6. View

11.

Girman C, Jacobsen S, Tsukamoto T, Richard F, Garraway W, Sagnier P . Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998; 51(3):428-36. DOI: 10.1016/s0090-4295(97)00717-6. View

12.

Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R . Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology. 2000; 56(4):610-6. DOI: 10.1016/s0090-4295(00)00724-x. View

13.

Walsh P, Madden J, Harrod M, Goldstein J, MACDONALD P, Wilson J . Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974; 291(18):944-9. DOI: 10.1056/NEJM197410312911806. View

14.

Jacobsen S, Girman C, Lieber M . Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1):5-16; discussion 16. DOI: 10.1016/s0090-4295(01)01298-5. View

15.

Bostwick D, Qian J, Civantos F, Roehrborn C, Montironi R . Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer. 2004; 2(4):228-35. DOI: 10.3816/cgc.2004.n.004. View

16.

Arrighi H, Metter E, Guess H, Fozzard J . Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology. 1991; 38(1 Suppl):4-8. DOI: 10.1016/0090-4295(91)80191-9. View

17.

Stamey T, Caldwell M, McNeal J, Nolley R, Hemenez M, Downs J . The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol. 2004; 172(4 Pt 1):1297-301. DOI: 10.1097/01.ju.0000139993.51181.5d. View

18.

Carter H, Landis P, Wright E, Parsons J, Metter E . Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?. J Urol. 2005; 173(6):2040-3. DOI: 10.1097/01.ju.0000158372.45211.47. View

19.

Jacobsen S, Jacobson D, Girman C, Roberts R, Rhodes T, Guess H . Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997; 158(2):481-7. DOI: 10.1016/s0022-5347(01)64508-7. View

20.

Roehrborn C, McConnell J, Lieber M, Kaplan S, Geller J, Malek G . Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999; 53(3):473-80. DOI: 10.1016/s0090-4295(98)00654-2. View